N-(3-ethylphenyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-ethylphenyl)benzamide
• 化学式: C₁₅H₁₅NO
• mdl: MFCD00442203
• 分子量: 225.29
• InChiKey: CBDGWGZKMPOIEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS<br/>[FR] DÉRIVÉS DE 1,2-BENZISOSÉLÉNAZOL-3(2H)-ONE ET DE 1,2-BENZISOTHIAZOL-3(2H)-ONE UTILISÉS COMME ADJUVANTS D'ANTIBIOTIQUES BÊTA-LACTAME
  申请人：UNIV HONG KONG POLYTECHNIC

  公开号：WO2019174279A1

  公开（公告）日：2019-09-19

  Provided herein are compositions and methods useful in the treatment of beta-lactam antibiotic resistant bacteria.

  本文提供了在治疗β-内酰胺类抗生素耐药细菌方面有用的组合物和方法。
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
  申请人：National Taiwan University

  公开号：US20140080848A1

  公开（公告）日：2014-03-20

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。
• PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS
  申请人：QIAN Dapeng

  公开号：US20110212053A1

  公开（公告）日：2011-09-01

  Provided are compounds according to Formula (I): or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R 1 , R 6 , R 7 , and R 8 are as defined, and which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

  提供了以下式子(I)的化合物，或其立体异构体、前药、多晶形或药学上可接受的盐形式，其中X、Y、R1、R6、R7和R8如定义所述，这些化合物是有效的PI3-激酶和/或其他医学和临床相关的激酶抑制剂。还提供了制备这些化合物和组合物作为PI3-激酶和激酶抑制剂的制药组合物和使用方法。更具体地，本发明的化合物为通过PI3-激酶和/或蛋白激酶活性调节或相关联的人类疾病，或其突变或变异形式提供治疗和治疗方法。
• Inhibitors of Hepatitis C virus NS3 serine protease
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2314598A1

  公开（公告）日：2011-04-27

  The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and_methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

  本发明涉及用于抑制蛋白酶，特别是丝氨酸蛋白酶，更特别是HCV NS3蛋白酶的化合物、方法和药物组合物。这些化合物以及利用它们的组合物和方法可单独或联合用于抑制病毒，特别是 HCV 病毒。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
  申请人：Tung Roger D.

  公开号：US20090143312A1

  公开（公告）日：2009-06-04

  The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.